The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2.
 
Michael Wang
Honoraria - Acerta Pharma; AstraZeneca; BeiGene; Breast-Gynecological International Cancer Society; CAHON; Chinese Anti-Cancer Association; Chinese Medical Association; Clinical Care Options; Dava Oncology; Epizyme; Hebei Cancer Prevention Federation; Imedex; Janssen Research & Development; Kite, a Gilead company; Miltenyi Biomedicine; Moffit Cancer Center; Mumbai Hematology Group; Newbridge Pharmaceuticals; OM Pharmaceutical Industries; Pharmacyclics/Janssen; Physicans' Education Resource; Scripps Health; The First Affiliated Hospital of Zhejiang University
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Bioinvent; CStone Pharmaceuticals; DTRM; Epizyme; Genentech; Guidepoint Global; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; Miltenyi Biomedicine; Oncternal Therapeutics; Pharmacyclics/Janssen; Pulse Biosciences; VelosBio
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Celgene; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Lilly; Loxo; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Javier Munoz
Honoraria - Kyowa Hakko Kirin; Seattle Genetics
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Fosun Kite; Genentech; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seattle Genetics
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seattle Genetics; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seattle Genetics
 
Andre Goy
Employment - OM Pharmaceutical Industries; Regional Cancer Care Associates
Leadership - COTA; Genomic Testing Cooperative; Resilience Care
Stock and Other Ownership Interests - COTA; Genomic Testing Cooperative; Resilience Care
Consulting or Advisory Role - AstraZeneca; Elsevier; Gilead Sciences; Janssen; Kite, a Gilead company (Inst); OncLive Peer Exchange; Physicans' Education Resource; Resilience Care; Vincera Pharma/Vincerx Pharma
Speakers' Bureau - Bristol-Myers Squibb/Celgene
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Infinity/Verastem (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Pharmacyclics (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Physicans' Education Resource
Other Relationship - AstraZeneca; MorphoSys/Incyte
 
Frederick L. Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Celgene; Cellular Biomedicine Group; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Novartis; Sana Biotechnology; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Caron Alyce Jacobson
Honoraria - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instill Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Consulting or Advisory Role - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instill Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Research Funding - Kite, a Gilead company; Pfizer
 
Brian T Hill
Honoraria - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis; Novartis; Pfizer; Pharmacyclics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Genentech (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
John Timmerman
Honoraria - Kite/Gilead
Consulting or Advisory Role - DAVA Oncology; Kite/Gilead
Research Funding - Bristol-Myers Squibb; ImmunGene; Kite, a Gilead company; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Houston Holmes
Leadership - Exuma Biotech
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene/Juno; Celgene; crispr therapeutics; Epizyme; Genentech; Janssen; Karyopharm Therapeutics; Kite/Gilead; Rigel; TG Therapeutics
Speakers' Bureau - Dova Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Rigel; Seattle Genetics
Research Funding - Adicet Bio (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene (Inst); Caribou Biosciences (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Unum Therapeutics (Inst); Viracta Therapeutics (Inst)
 
Ian W. Flinn
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Century Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Hutchison MediPharma (Inst); Iksuda Therapeutics (Inst); Innocare (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seattle Genetics (Inst); SERVIER (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CALIBR (Inst); Celgene (Inst); City of Hope (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Curis (Inst); Fate Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seattle Genetics (Inst); TCR2 Therapeutics (Inst); Tessa Therapeutics (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
David Bernard Miklos
Honoraria - fosun Kite Biotechnology; Janssen
Consulting or Advisory Role - Adaptive Biotechnologies; Janssen; Juno/Celgene; Pharmacyclics
Research Funding - Adaptive Biotechnologies; Adicet Bio; Alimera Sciences; Kite, a Gilead company; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
 
John M. Pagel
Employment - Loxo
Leadership - Loxo
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Actinium Pharmaceuticals; AstraZeneca; BeiGene; Epizyme; Gilead Sciences; Loxo; MEI Pharma; MorphoSys; TG Therapeutics
 
Marie José Kersten
Honoraria - Kite, a Gilead company; Novartis; Roche
Consulting or Advisory Role - Kite, a Gilead Company; Miltenyi Biotec (Inst); Novartis; Takeda (Inst)
Research Funding - Kite, a Gilead company (Inst)
Travel, Accommodations, Expenses - Celgene; Kite, a Gilead Company; Novartis; Roche
 
Roch Houot
Honoraria - ADC Therapeutics; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Kite, a Gilead Company; Novartis; Roche
Consulting or Advisory Role - Kite, a Gilead Company
 
Amer Beitinjaneh
Consulting or Advisory Role - Kite, a Gilead company
Research Funding - Atara Biotherapeutics; Kite/Gilead
 
Weimin Peng
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Xiang Fang
No Relationships to Disclose
 
Rhine Shen
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite/Gilead
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics
 
Rubina Siddiqi
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Ioana Kloos
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite, a Gilead company
 
Patrick Michael Reagan
Consulting or Advisory Role - Kite, a Gilead company
Research Funding - Genentech/Roche; Seattle Genetics